Looking ahead to 2018, the most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms.
That comes with a catch. Consumers are more sensitive than ever to high prices, with more than 30 states introducing legislation on drug pricing. Given the current political climate, the market is likely to place a premium on novel therapies that truly advance the standard of care. Indeed, next year's most promising late-stage candidates run the gamut, from drugs with never-before-seen mechanisms to old standbys with new potential.
The products featured in this pipeline report cover the following major areas:
Other key products in the pipeline cover genetic and/or multifactorial disorders, infectious disease, women’s health and orphan.
* The link leads you to an external websites that is not provided or maintained by or in any way affiliated with GfK SE. Please note that GfK SE does not guarantee the accuracy, relevance, timeliness, or completeness of any information on these external websites. GfK SE is not responsible for the content of the external website.